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Summary
Familial nonmedullary thyroid cancer (FNMTC) is a
clinical entity characterized by a phenotype more ag-
gressive than that of its sporadic counterpart. Families
with recurrence of nonmedullary thyroid cancer
(NMTC) have been repeatedly reported in the literature,
and epidemiological data show a very high relative risk
for first-degree relatives of probands with thyroid cancer.
The transmission of susceptibility to FNMTC is com-
patible with autosomal dominant inheritance with re-
duced penetrance, or with complex inheritance. Cases
of benign thyroid disease are often found in FNMTC
kindreds. We report both the identification of a new
entity of FNMTC and the mapping of the responsible
gene, named “TCO” (thyroid tumors with cell oxyphi-
lia), in a French pedigree with multiple cases of multi-
nodular goiter and NMTC. TCO was mapped to
chromosome 19p13.2 by linkage analysis with a whole-
genome panel of microsatellite markers. Interestingly,
both the benign and malignant thyroid tumors in this
family exhibit some extent of cell oxyphilia, which, until
now, had not been described in the FNMTC. These find-
ings suggest that the relatives of patients affected with
sporadic NMTC with cell oxyphilia should be carefully
investigated.
Introduction
Thyroid neoplasms can be solitary or multiple, present-
ing clinically as uninodular or multinodular goiter
(MNG), respectively. Thyroid carcinomas of follicular-
cell origin have been repeatedly recorded as occurring
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in families (Lote et al. 1980; Cooper et al. 1981; Couch
et al. 1986; Stoffer et al. 1986; Ozaki et al. 1988; Gorson
1992; Grossman et al. 1995; Burgess et al. 1997;
Kraimps et al. 1997), and the proportion of these fa-
milial nonmedullary thyroid carcinomas (FNMTC
[MIM 188550]) is estimated to be ∼3%–7% of all thy-
roid tumors. These kindreds typically show two to four
affected relatives, with as many as eight cases of FNMTC
in the same family (Lote et al. 1980; Burgess et al. 1997).
Recent studies (Grossman et al. 1995) have indicated
that FNMTC is, in contrast to sporadic cases, usually
multifocal, recurs more frequently, and shows an early
age at onset. This is well exemplified by familial ade-
nomatous polyposis–associated thyroid carcinoma,
which, in addition, has been found to be a distinct mor-
phological entity, rather than the papillary carcinoma
that it previously had been believed to be (Harach et al.
1994). The mode of inheritance of some FNMTC is not
clear. Most published pedigrees are compatible with in-
heritance of one autosomal dominant gene with reduced
penetrance, but polygenic inheritance cannot be ex-
cluded. Epidemiological data show a very high relative
risk for first-degree relatives of probands with thyroid
cancer (Goldgar et al. 1994), but large families with
many cases of thyroid cancer are rare, a situation that
suggests, again, a possible polygenic inheritance. These
hypotheses are supported also by the analysis of 125
pedigrees, each with at least two members affected with
NMTC, collected through the international consortium
for the study of genetic susceptibility to NMTC (see the
Geocities Website). The structures of the families of this
collection suggest a complex situation of genetic hetero-
geneity, polygenic inheritance, and gene-environment in-
teraction. Studying complex traits is very difficult. How-
ever, rare monogenic forms of diseases that are otherwise
inherited as complex traits do exist. In these cases the
identification of the genes involved can give insights into
the more widespread polygenic form of the trait.
One peculiar form of thyroid tumors is characterized
by the presence of cell oxyphilia. Oxyphil cells are found
in a minority of thyroid tumors, either benign or malig-
nant. They are characterized by the presence of a large
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volume of granular eosinophilic cytoplasm, and they are
very rich in mitochondria. Tumors with cell oxyphilia
are frequently associated with autoimmune thyroiditis.
There is substantial controversy about the classification
and behavior of tumors with cell oxyphilia. Their oc-
currence in families has been reported elsewhere (Katoh
et al. 1998), and here we report the mapping, to chro-
mosome 19p13, of a gene responsible for familial thy-
roid tumors with cell oxyphilia.
Patients, Material, and Methods
Patients
Family PL, whose pedigree is shown in figure 1, had
been previously reported in a series of seven families
affected with familial papillary thyroid carcinoma (PTC)
(Kraimps et al. 1997). In brief, in this three-generation
family from a nonendemic-goiter area of western France,
six individuals were affected with MNG, and three were
affected with PTC. Six patients were followed up by two
of us (J.B. and J.-L.K.) in the endocrine-surgery unit in
the hospital in Poitiers. Of these six individuals, five
underwent thyroid surgery, and the sixth (III-5) was con-
sidered as affected because he was shown to have MNG,
by both thyroid palpation and echography. Complete
clinical and pathological information was obtained from
the remaining three affected subjects, who were followed
up elsewhere. The age range at which each affected in-
dividual was operated on was 10–63 years (mean 24
years). PTCs were diagnosed in individuals II-5, III-3,
and III-7 at the ages of 41, 27, and 11 years, respectively.
Thyroid-tumor recurrence occurred in four patients dur-
ing follow-up. None of the patients had history of any
other type of cancer-prone syndrome or radiation ex-
posure. There is no history of autoimmune disease in
the family. Individuals III-2, III-4, and III-6 were con-
sidered “unaffected” because the results of clinical ex-
amination and thyroid-image analysis were normal. All
clinical and ultrascintigraphic examinations were per-
formed before the molecular studies were started.
Genotyping
Blood samples were collected from the nine affected
persons and from eight unaffected relatives (spouses and
siblings of patients), after their informed consent was
obtained, according to the French law. Genomic DNAs
were extracted according to a standard phenol-chloro-
form protocol. The 17 samples were genotyped with
microsatellite markers from the Cooperative Human
Linkage Center, the Ge´ne´thon collections, or other
sources (Collin et al. 1996). Heterozygosity was 170%
for all markers, and the average spacing between the
markers used in the genome scan was 12 cM. Each PCR
reaction included 1# PCR buffer, 1.5 mM MgCl2, 200
mM of each dNTP, 50 ng DNA, 0.2 U Red Hot DNA
polymerase (Advanced Biotechnologies), and 5 pmol of
each primer (one of them fluorescently labeled), for a
total volume of 8 ml. Alternatively, unlabeled primers
were used, and the PCR reactions were supplemented
with 0.5–2 mM fluorescently labeled dCTP (Perkin-El-
mer). The reactions were run in a 9600 GeneAmp PCR
System (Perkin-Elmer), with the following thermal pro-
file: 96C for 5 min; 30 cycles of 94C for 30 s, 53C
for 30 s, and 72C for 30 s; and final extension at 72C
for 5 min. The fluorescent products for each template
were appropriately pooled, and an aliquot was loaded
onto a 4.8% polyacrylamide 8-M urea gel and was run
in an automated sequencer (model 377; Applied Biosys-
tems). The data were automatically collected and ana-
lyzed by GeneScan and Genotyper software (Applied
Biosystems).
Linkage Analysis
Linkage power for this family was studied by a sim-
ulation by means of the SLINK and MSIM programs of
the LINKAGE package, version 5.1 (Ott 1989). Patients
with MNG, PTC, or both were considered as equally
affected. Two-point linkage analysis was performed with
the MLINK program of LINKAGE (Lathrop and Lalou-
el 1984). Parametric and nonparametric multipoint anal-
ysis was performed with Genehunter (Kruglyak et al.
1996). For the parametric analysis, the trait was assumed
to be autosomal dominant, with a disease-allele fre-
quency of .001 and penetrance of .85. Allele frequencies
for the microsatellite markers either were obtained from
Genome Database and the Cooperative Human Linkage
Center or were considered as equal (i.e., 1/no. of alleles).
Morphological Studies
Bouin-and-formalin–fixed, paraffin-embedded and
hematoxylin-eosin–stained histological sections from
cases I-1, II-5, II-7, III-3, and III-7 were available for
histology. Representative slides from all cases were also
studied for the presence of thyroglobulin and calcitonin,
by an immunoperoxidase method.
Results
Linkage Mapping
Segregation of the disease in the family shows the
presence of a single disease gene with an autosomal dom-
inant mode of inheritance and very high penetrance.
Simulation of linkage with SLINK and MSIM in family
PL yielded a maximum LOD score (Zmax) of 2.97 at a
recombination fraction (v) of 0 and 100% penetrance.
A random genome screening was undertaken. Markers
intragenic or mapping near major candidate genes
(whose alterations have been frequently reported in he-
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Table 1
Analysis of Linkage of MNG and Thyroid Carcinoma Susceptibility
to Chromosome 19p13.2
MARKER
LOD SCORE AT v 
Zmax vmax.00 .01 .05 .10 .20 .30 .40
D19S1034 7.61 1.09 .15 .55 .72 .61 .36 .72 .18
D19S884 1.61 .34 .89 1.01 .93 .70 .38 1.02 .12
D19S391 1.74 1.72 1.61 1.48 1.18 .84 .45 1.74 .00
D19S916 3.01 2.96 2.77 2.51 1.95 1.32 .65 3.01 .00
D19S413 2.95 2.90 2.70 2.45 1.90 1.28 .63 2.95 .00
D19S586 2.41 2.37 2.21 2.00 1.54 1.03 .49 2.41 .00
D19S583 .60 .59 .54 .47 .32 .17 .05 .60 .00
D19S535 2.40 2.36 2.20 2.00 1.50 1.00 .48 2.40 .00
D19S221 1.31 .63 1.17 1.27 1.13 .84 .46 1.27 .10
D19S432 1.30 .91 1.43 1.50 1.32 .98 .53 1.50 .08
Figure 1 Pedigree of family PL, with haplotype analysis in the region of linkage to susceptibility to thyroid cancer and MNG, on
chromosome 19. Circles represent females, and squares represent males; unblackened symbols denote unaffected individuals, blackened symbols
denote cases of thyroid cancer, and half-blackened symbols denote cases of MNG. In parentheses are the ages at diagnosis/surgery of the family
members affected with NMTC or MNG. Critical recombinations in individuals II-3 and II-5 define a 2-9-5-6-2-2 haplotype that is coinherited
with the disease and that is not shared by the unaffected family members.
reditary or sporadic thyroid tumors) yielded negative
LOD scores. After genotyping a total of 226 microsa-
tellites covering ∼75% of the genome, we found a LOD
score of 2.41 at , for marker D19S586. Additionalv  0
markers were typed in the region (to a density as high
as 10 markers/21.5 cM) and were found to be in linkage,
with LOD scores peaking at markers D19S916
( at ) and D19S413 ( atZ  3.01 v  0 Z  2.95max max
). Table 1 summarizes the findings. The LOD scoresv  0
did not change significantly if calculated with different
values of penetrance (data not shown). The information
content calculated by Genehunter (Kruglyak et al. 1996)
was 100% for markers D19S916 and D19S413, thus
explaining why a LOD score equal to the theoretical
maximum has been reached. Although the trait is very
likely to be transmitted in an autosomal dominant fash-
ion with high penetrance, its mode of inheritance is not
known a priori; therefore, we also performed a non-
parametric multipoint analysis of the data, with Gene-
hunter. The result was an nonparametric-linkage score
of 9.1 ( ) throughout the region of linkage,P  .0048
thus corroborating the result of the parametric analysis
(data not shown). Haplotypes for the region of linkage
were reconstructed in the family (fig. 1), and critical
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Figure 2 Two well-circumscribed tumors separated by normal
thyroid tissue and predominantly composed of papillary structures
lined by oxyphil cells (#45; hematoxylin and eosin).
Figure 3 Adenoma showing follicular structures lined by cells
with oxyphil cytoplasm and regular, sometimes apical nuclei with con-
spicuous nucleoli. Nuclear grooving and cytoplasmic inclusions are
not seen (#220; hematoxylin and eosin).
Figure 4 Papillary carcinoma. Oxyphil cells forming papillary (upper left), follicular (upper right), and solid (lower left) structures (#180;
hematoxylin and eosin). At the lower right the oxyphil cells show irregular, often-grooved nuclei, an occasional nuclear-cytoplasmic inclusion,
and conspicuous nucleoli. Note the fragmented psammoma body at the lower right (#290; hematoxylin and eosin).
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recombinations in individuals II-5 and II-3 identified a
region of linkage, encompassing markers DS19S391–2.5
cM–D19S916–1.1 cM–D19S413–0.55 cM–D19S586–0
cM–D19S583–0.8 cM–D19S535. The interval between
the closest unlinked markers on either side (D19S884
and D19S221) is 9.8 cM (on the basis of a map of the
Marshfield Medical Research Foundation). In fact, since
patient I-1 is homozygous at marker locus D19S391 (fig.
1), it is equally probable that the critical interval lies in
the 7.4 cM between D19S391 and D19S221. The mark-
ers defining the region of linkage have been physically
mapped to a region of chromosome 19p13.2, spanning
∼4 Mb (Ashworth et al. 1995; also see the “Maps of
Human Chromosome 19” Website).
Histopathological Findings
Histology results available from five cases showed
multiple, usually well-demarcated tumors of varying
sizes, composed of follicular structures, papillae, solid/
trabecular areas, or an admixture. The neoplastic cells
from the majority of the lesions showed variable cyto-
plasmic eosinophilia (figs. 2–4). Tumors from cases I-1
and II-7 showed no evidence of malignancy and were
regarded as multiple adenomas with variable cell oxy-
philia (fig. 3). Cases II-5 and III-3 showed, in addition,
malignant tumors that were regarded as oxyphil papil-
lary carcinoma (fig. 4). Histology results available from
case III-7 showed an invasive single oxyphil-cell tumor
showing neither classic nuclear features of papillary car-
cinoma nor psammoma bodies, which therefore was
classified as oxyphil-cell carcinoma. All tumors showed
thyroglobulin immunoreactivity and were negative for
calcitonin. Nonnodular background thyroid tissue was
unremarkable in all cases.
Discussion
Here we have presented evidence for a new entity of
genetic disease, characterized by thyroid carcinomas and
adenomas, multiple or isolated, with cell oxyphilia and
a compound architecture of follicular, papillary, and
solid structures, not resembling any of the typical sub-
classes of thyroid tumors. Adenomas and carcinomas
share the same properties and represent only different
stages of progression to malignancy. We mapped, by
linkage analysis in a French family, a gene on chromo-
some 19p13.2, named “TCO” (thyroid tumors with cell
oxyphilia), that accounts for susceptibility to this
phenotype.
A proportion of sporadic thyroid tumors of follicular-
cell origin shows some of the features present in family
PL—that is, cell oxyphilia with variable architecture.
Also, occasional familial aggregation has been suggested
for this type of tumor (Katoh et al. 1998). The latter
may represent the entity that we are herein describing,
in which adenomas and carcinomas share some mor-
phological properties.
The susceptibility to thyroid tumors, which we have
described here for the first time and have characterized
from the morphological and genetic point of view, is
distinct from previously reported hereditary predispo-
sition to thyroid disease. Three conditions are known to
be associated with hereditary predisposition to nonmed-
ullary thyroid tumors; one is familial adenomatous poly-
posis coli (Harach et al. 1994), the second is Cowden
syndrome (Liaw et al. 1997), and the third is a form of
MNG and PTC (Bignell et al. 1997; MIM 138800). The
tumors found in family PL are morphologically distinct
from those observed in these three conditions. During
the genome scan, we excluded linkage to the involved
genes (APC, PTEN, and MNG1, respectively). Linkage
to another important candidate gene, TSHR, whose so-
matic mutations are found in sporadic thyroid adenomas
(Parma et al. 1993) and whose germ-line mutations pre-
dispose to familial hyperthyroidism (Duprez et al. 1994),
has been excluded by use of an intragenic marker. We
excluded, as well, linkage to RET, TRK, and MET, three
oncogenes that are known to be frequently altered in
sporadic NMTC (Bongarzone et al. 1989; Di Renzo et
al. 1992; Pasini et al. 1996). Studying somatic alterations
of these genes in the tumors of family PL will be of great
interest, since it will provide clues to the mechanism of
action of the TCO-gene product.
Several genes have been mapped in the critical area
of linkage (Ashworth et al. 1995), although none ap-
pears as a striking candidate for the indentification of
TCO. Among the genes mapping to 19p13.2, ICAM1
is expressed in PTCs and is silent in normal thyroid tissue
(Nakashima et al. 1994). Several zinc-finger–protein
genes also map to the region of interest. Moreover, the
oncogene JUNB is localized just at the centromeric bor-
der of the region of linkage (Ashworth et al. 1995).
Once TCO has been cloned and its identity elucidated,
it will be of interest to verify its involvement in the eti-
ology of thyroid tumors with cell oxyphilia—that is, to
search both for TCO germ-line mutation in hereditary
and apparently sporadic cases and for somatic mutations
in sporadic ones. Our findings should prompt clinicians
to investigate the family history of patients with non-
medullary thyroid carcinoma, adenoma, or MNG show-
ing morphological features similar to those described
here.
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